Promius Pharma, LLC
200 Somerset Corporate Boulevard
21 articles with Promius Pharma, LLC
Dr. Reddy’s Laboratories Announces Entering into a Definitive Agreement to Sell Its Neurology Branded Products to Upsher-Smith Laboratories, LLC
Dr. Reddy’s Laboratories Ltd. announces that it has entered into a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC, pursuant to which Dr. Reddy’s would sell its US and select territory rights for ZEMBRACE® SYMTOUCH® 3 mg and TOSYMRA™ 10 mg, which are commercialized through its wholly owned subsidiary, Promius Pharma, LLC.
Dr. Reddy's Laboratories and its U.S. subsidiary, Promius Pharma, announced U.S. FDA approval on January 28 for its migraine treatment TOSYMRA™ in the United States
Dr. Reddy's Laboratories and Its U.S. Subsidiary, Promius Pharma, Announce FDA Approval for TOSYMRA™ (Sumatriptan Nasal Spray) 10 mg, in the U.S. Market
Dr. Reddy's Laboratories Ltd. and its subsidiary, Promius Pharma, LLC announced the approval of TOSYMRA (previously known as DFN-02) by the U.S. Food and Drug Administration (FDA).
Promius Pharma Announces Launch of "My Skin Matters," An Empowerment Movement for People with Skin Conditions
Promius Pharma announced the launch of My Skin Matters, a fearless movement for people living with eczema, psoriasis, acne, and other skin conditions.
Perrigo Company plc (NYSE; TASE: PRGO) announced today that Promius Pharma, LLC initiated patent litigation on May 22, 2018.
Dr. Reddy's Laboratories and its U.S. subsidiary Promius Pharma announce the filing of an NDA for its migraine candidate
Dr. Reddy's Laboratories Ltd. and its subsidiary, Promius Pharma, LLC, today announced the filing of New Drug Application (NDA) for its migraine candidate DFN-02 with the U.S. Food and Drug Administration (USFDA).
Promius Pharma Announces ZEMBRACE SymTouch (Sumatriptan Injection) 3 mg Achieves Primary Endpoint in Post-Approval Clinical Trial
Overall, the trial found that a significantly higher proportion of subjects experienced migraine pain freedom at 2 hours postdose with ZEMBRACE SymTouch compared with placebo: 51.0% versus 30.8%,.
This short-contact formulation is expected to bring a new dimension to the treatment of acne patients.
Promius Pharma, LLC Presents Positive Results For Phase II Study Of DFN-02, A Novel Intranasal Formulation Of Sumatriptan, At 18th Congress Of The International Headache Society
Promius Pharma, LLC Announces Positive Results For Phase II Study Of DFN-02, A Novel Intranasal Formulation Of Sumatriptan
Promius Pharma, LLC Launches NoTime4Migraines, An Online Resource About Migraine Symptoms And Potential Treatment Options
Promius Pharma, LLC Will Present Results Of Additional Analysis Of The American Migraine Prevalence And Prevention Study (AMPP) In Vancouver At The 68th American Academy of Neurology Annual Meeting, April 15-21, 2016
Promius Pharma, LLC Release: ZEMBRACE Symtouch (Sumatriptan Injection) 3 Mg, Approved By The FDA In January 2016 For The Acute Treatment Of Migraine With Or Without Aura In Adults, Is Now Commercially Available In The U.S.
Dr. Reddy's Laboratories Ltd. And Its Subsidiary Promius Pharma, LLC Announce The Filing Of Three NDAs With The USFDA
Promius Pharma, LLC and Valeant Pharmaceuticals International Form Collaboration to Market Cloderm(R) Cream in the United States
Dr. Reddy's Laboratories Ltd. Wholly-Owned Subsidiary Promius Pharma, LLC Launches EPICERAM(R) Skin Barrier Emulsion